

Semorinemab

Cat. No.:	HY-P99399
CAS No.:	2159141-27-0
Target:	Tau Protein
Pathway:	Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a K_d value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease ^[1] .	
In Vitro	Semorinemab binds to human Tau and recombinant cynomolgus monkey Tau with K_d values of 3.8 and 11.2 nM, respectively ^[1] . Semorinemab prevents neurons to uptake oligomeric Tau ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Semorinemab (3, 10 and 30 mg/kg; i.p., once weekly for 13 weeks) reduces accumulation of Tau pathology in a transgenic (Tg) mouse model of tauopathy ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Tg mouse with the expression of human disease-causing tau mutant (TauP301L-Tg) ^[1]
	Dosage:	3, 10 and 30 mg/kg
	Administration:	Intraperitoneal injection; 3, 10 and 30 mg/kg, once weekly for 13 weeks
	Result:	Reduced the accumulation of pathological tau, and dose-dependently decreased pTau212/214 and pTau202/205.

REFERENCES

[1]. Ayalon G, et al. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. *Sci Transl Med.* 2021 May 12;13(593):eabb2639.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA